MannKind Corporation (MNKD)
Automate Your Wheel Strategy on MNKD
With Tiblio's Option Bot, you can configure your own wheel strategy including MNKD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MNKD
- Rev/Share 0.9894
- Book/Share -0.1805
- PB -30.804
- Debt/Equity -0.8507
- CurrentRatio 2.4952
- ROIC 0.1819
- MktCap 1705932997.0
- FreeCF/Share 0.0944
- PFCF 59.2585
- PE 51.6956
- Debt/Assets 0.1137
- DivYield 0
- ROE -0.326
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MNKD | H.C. Wainwright | -- | Buy | -- | $9 | July 16, 2025 |
| Initiation | MNKD | Mizuho | -- | Outperform | -- | $12 | April 10, 2025 |
| Initiation | MNKD | Wedbush | -- | Outperform | -- | $11 | Feb. 10, 2025 |
| Initiation | MNKD | Wells Fargo | -- | Overweight | -- | $9 | Dec. 20, 2024 |
| Upgrade | MNKD | RBC Capital Mkts | Sector Perform | Outperform | $7 | $10 | Dec. 19, 2024 |
| Resumed | MNKD | Leerink Partners | -- | Outperform | $7 | $8 | Sept. 9, 2024 |
News
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its option—granted under the companies' 2018 license and collaboration agreement—to develop a second dry powder inhalation therapy.
Read More
New Strong Sell Stocks for August 27th
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Negative
CVGI, INBK and MNKD have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2025.
Read More
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
Published: August 25, 2025 by: Benzinga
Sentiment: Positive
MannKind Corporation MNKD on Monday agreed to acquire scPharmaceuticals Inc. SCPH for a deal value of up to approximately $360 million, or $5.35 per share.
Read More
MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
MannKind (MNKD) Reports Break-Even Earnings for Q2
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
MannKind (MNKD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.05 per share a year ago.
Read More
Analysts Estimate MannKind (MNKD) to Report a Decline in Earnings: What to Look Out for
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Negative
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit Grand Prix in downtown Detroit.
Read More
MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
MannKind Corporation (NASDAQ:MNKD ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants Michael Castagna – Chief Executive Officer Chris Prentiss – Chief Financial Officer Conference Call Participants Olivia Brayer – Cantor Anish Nikhanj – RBC Andreas Argyrides – Oppenheimer & Co. Yun Zhong – Wedbush Anthony Petrone – Mizuho Operator Good morning, and welcome to the MannKind Corporation First Quarter 2025 Financial Results Earnings Call. As a reminder, this call is being recorded on May 08, 2025, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call …
Read More
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
MannKind (MNKD) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago.
Read More
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 2024 1Q 2025 net income of $13M, + 24% v.
Read More
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
Published: April 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Daly to showcase striking “Tired of Pricks?” livery for JHR at Acura Long Beach Grand Prix, Sunday, April 13 Indiana native is the only known U.S. pro racing driver competing full-time with T1D WESTLAKE VILLAGE, Calif.
Read More
MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
MannKind Corporation (NASDAQ:MNKD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Corporate Participants Michael Castagna - Chief Executive Officer Chris Prentiss - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Andreas Argyrides - Oppenheimer Brandon Folkes - Rodman & Renshaw Yun Song - Wedbush Securities Operator Good afternoon and welcome to the MannKind Corporation Fourth Quarter and Year End 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on February 26, 2025 and will be available for playback …
Read More
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
About MannKind Corporation (MNKD)
- IPO Date 2004-07-28
- Website https://www.mannkindcorp.com
- Industry Biotechnology
- CEO Michael E. Castagna
- Employees 403